Introduction to Pipeline
The Opterion lead development product is the osmotic driver (ODR) Opt100.
It is an innovative and proprietary composition of short-chain glucose polymers and maltose, which allows accelerated ultrafiltration, high versatility regarding dwell times and minimizes impact on glucose metabolism.
Opt100 is currently in preclinical development with the goal of starting clinical development in 2022.
Opterion is also investigating whether the polyphenol resveratrol can be used as a biocompatibility enhancing agent (BCA) in peritoneal dialysis fluids. Resveratrol was shown to reduce peritoneal cytotoxicity in PD fluids1.
1 Grentzmann 2017, WO2017013120 (A1)